Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
03/09/17
Dimension Therapeutics Corporate Presentation March 2017
Download Documentation
PDF
Stock
DMTX (Common Stock) $1.70 - 0.05 (2.86%)
High $1.75
Events
Dimension Therapeutics Q4 2016 Earnings and Corporate Update Conference Call
03/09/17 8:30 a.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
March 09, 2017
Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017 Updates interim results from Phase 1/2 clinical program for DTX101 in hemophilia B Conference call today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key [...]  Read More /
March 07, 2017
Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that it will report financial results for the full year ended December 31, 2016, on Thursday, March 9, 2017. Following distribution of the earnings release via wire services, Dimension Therapeutics will host a live conference call and webcas[...]  Read More /
February 07, 2017
Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the election of John A. Hohneker, M.D., Executive Vice President, Head of Research and Development of FORMA Therapeutics Inc., to Dimension’s Board of Directors (the “Board”). Dr. Hohneker brings over 25 years’ global experience in pharmaceut[...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.